Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

marketwatch.com - NervGen Pharma Shares Slide After Disclosing Public Offering
NervGen Pharma Shares Slide After Disclosing Public Offering
MarketWatch

Shares of NervGen Pharma slid after the company commenced an underwritten public offering of common shares and warrants. The stock declined 17% to $3.06 in after-hours trading Thursday. Shares, which began trading on Nasdaq in January, had lost…

globenewswire.com - TME Pharma NV - TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
GlobeNewswire

TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS Berlin, Germany, May 21, 2026, 18.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the…

fool.com - Motley Fool Transcribing - Lantern Pharma (LTRN) Q1 2025 Earnings Transcript
Lantern Pharma (LTRN) Q1 2025 Earnings Transcript
The Motley Fool

Thursday, March 27, 2025 at 4:30 p.m. ET President and CEO — Panna Sharma Chief Financial Officer — David Margrave Need a quote from a Motley Fool analyst? Email [email protected] LP-184 Phase 1a Enrollment -- Over 50 patients have…

thehindu.com - The Hindu Bureau - Aurobindo Pharma Q4 net up 2% to ₹921 cr
Aurobindo Pharma Q4 net up 2% to ₹921 cr
The Hindu

Aurobindo Pharma's consolidated net profit for the March quarter rose 2% to ₹921 crore compared to the ₹903 crore a year earlier. Revenue from operations of the Hyderabad-headquartered generic drugmaker increased 5.6% to ₹8,853…

globenewswire.com - Orion Oyj - Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO Annual Meeting
Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO Annual Meeting
GlobeNewswire

Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO Annual Meeting First clinical data from the Phase 1/2 TEADES trial of ODM-212 to be presented at ASCO 2026 ODM-212 is an…

thehindu.com - N. Ravi Kumar - India collating inputs on hurdles for pharma exports to 8 Asian countries
India collating inputs on hurdles for pharma exports to 8 Asian countries
The Hindu

India has initiated an exercise to identify and seek resolution for market access issues its drugs and pharmaceuticals face in SAARC countries and Iran. The Foreign Trade (South Asia) Division in the Department of Commerce is collecting inputs on…

thehindubusinessline.com - Aurobindo Pharma's Q4 net up 2% to ₹921 crore
Aurobindo Pharma's Q4 net up 2% to ₹921 crore
BusinessLine

Aurobindo Pharma's consolidated net profit increased 2 per cent to ₹921 crore in Q4 FY26 compared to ₹903 crore in the year-ago period. The total revenue of the Hyderabad-based company grew 5.6 per cent to ₹8,853 crore…

energyandcapital.com - Google's $2 Billion Bet to Solve Big Pharma's 10^60 Problem
Google's $2 Billion Bet to Solve Big Pharma's 10^60 Problem
Energy & Capital -

Don't worry, there's nothing wrong with you. Truth is, nobody can. We're talking about a number with 60 zeros! To put a little perspective on this number, it's more than every atom in the observable universe, and more than every star in every…

benzinga.com - Mohd Haider - Liminatus Pharma Is Trending Overnight - Here's Why LIMN Stock Surged Over 79% In After-Hours Session - L
Liminatus Pharma Is Trending Overnight - Here's Why LIMN Stock Surged Over 79% In After-Hours Session - L
Benzinga

Liminatus Pharma Inc. (NASDAQ:) shares are trending on Friday. LIMN shares surged 79.34% to $0.34 after the bell on Thursday. The stock of the biopharmaceutical company had experienced an intraday drop of 1.16%, closing at $0.19, according to…

marketbeat.com - Fideuram Intesa Sanpaolo Private Banking S.P.A. Invests $4.92 Million in Royalty Pharma PLC $RPRX
Fideuram Intesa Sanpaolo Private Banking S.P.A. Invests $4.92 Million in Royalty Pharma PLC $RPRX
MarketBeat

Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission…

marketbeat.com - Royalty Pharma (NASDAQ:RPRX) Hits New 12-Month High - What's Next?
Royalty Pharma (NASDAQ:RPRX) Hits New 12-Month High - What's Next?
MarketBeat

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Thursday. The company traded as high as $53.48 and last traded at $53.43, with a volume of 1724718 shares traded. The stock had…

thehindu.com - Pti - Stock markets rally in early trade tracking positive trend in global peers, easing oil prices
Stock markets rally in early trade tracking positive trend in global peers, easing oil prices
The Hindu

Benchmark equity indices were trading higher in early trade on Thursday (May 21, 2026), helped by easing oil prices and a sharp rally in global markets amid hopes that the West Asia conflict would end soon. The 30-share BSE Sensex climbed 327.74…

rediff.com - Nandita Malik - Indian Stock Market Rally: Sensex, Nifty Up Amid Global Optimism, Lower Oil Prices
Indian Stock Market Rally: Sensex, Nifty Up Amid Global Optimism, Lower Oil Prices
Rediff.com

Indian benchmark equity indices, Sensex and Nifty, surged in early trade, buoyed by a positive global market rally and a significant drop in crude oil prices, as investors anticipate a swift resolution to the West Asia conflict. Indian benchmark…

statnews.com - Elaine Chen - Lilly's 'triple-G' drug leads to bariatric-surgery levels of weight loss in trial
Lilly's 'triple-G' drug leads to bariatric-surgery levels of weight loss in trial
STAT

Eli Lilly reported Thursday that in a late-stage trial, its next-generation obesity drug led to levels of weight loss approaching the effectiveness seen with bariatric surgery, but that there were high rates of side effects and discontinuations…

forbes.com - Javier Hasse - Cannabis Prices Keep Falling. New Global Report Says That Was Always Going To Happen
Cannabis Prices Keep Falling. New Global Report Says That Was Always Going To Happen
Forbes

Cannabis prices keep falling. It's not unexpected. A new analysis from Whitney Economics and GCNC argues that cannabis price compression is not a market failure, but a predictable phase of legalization that regulators and operators repeatedly…

Receive a Daily briefing on Pharma Industry News

Get Started